Atrogi AB, a clinical stage biotech company pioneering novel GPCR pathway-signalling modulators to transform metabolic and muscle health, today announces that the first subjects have been dosed in a ...
Morning Overview on MSN
Light-switchable beta blocker could target tissues and cut side effects
A new class of beta blockers designed to activate only when struck by specific wavelengths of light could allow doctors to ...
Recent clinical studies have suggested that phenylacetylglutamine (PAGln), a novel gut microbial metabolite, can mechanistically modulate patients' risk of developing cardiovascular disease (CVD) and ...
Cleveland Clinic researchers have made a significant discovery about how the gut microbiome interacts with cells to cause cardiovascular disease. The Nature Communications study found ...
Rendering a drug effective or ineffective in a flash at the appropriate location – this is the focus of research in ...
Beta3-adrenergic receptors (β3-AR) have emerged as pivotal modulators of cardiac performance, particularly in the context of heart failure. Distinct from the classical β1/β2-adrenergic signalling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results